- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.05. | Immunovia AB: Bulletin From The Annual General Meeting On 13 May 2026 In Immunovia AB (publ) | 171 | GlobeNewswire (Europe) | Today, on 13 May 2026, the annual general meeting of Immunovia AB (publ) was held. A summary of the adopted resolutions follows below.
Resolution on the adoption of the accounts and allocation of resultThe... ► Artikel lesen | |
| 07.05. | Immunovia AB: Immunovia Publishes Interim Report for January-March 2026 | 273 | GlobeNewswire (Europe) | Highlights January-March 2026Net sales and operating results for Q1 2026 in line with expectations: Net sales of 374 KSEK (139) for the period included royalties and revenues from PancreaSure tests.... ► Artikel lesen | |
| 24.02. | Immunovia AB: Immunovia Publishes Full Year Report for 2025 | 381 | GlobeNewswire (Europe) | Highlights October-December 2025Net sales and operating results for Q4 2025 in line with expectations: Net sales of 354 KSEK for the period (455) largely reflected royalty revenue. Operating loss was... ► Artikel lesen | |
| 20.01. | Immunovia AB: The Board of Directors of Immunovia withdraws proposal for reverse share split and cancels Extraordinary General Meeting | 162 | GlobeNewswire (Europe) | Following discussions with major shareholders, the Board of Directors of Immunovia AB (publ) ("Immunovia" or the "Company") has decided to withdraw the proposal for a reverse share split and the Extraordinary... ► Artikel lesen | |
| 19.01. | Immunovia AB: Immunovia receives state regulatory approval for PancreaSure in California and initiates commercial rollout | 272 | GlobeNewswire (Europe) | Immunovia AB (IMMNOV: Nasdaq Stockholm), a pancreatic cancer diagnostics company, today announced that it has received regulatory approval for its PancreaSure test in California, US, enabling commercial... ► Artikel lesen | |
| 17.12.25 | Immunovia AB: The Board of Directors of Immunovia proposes a reverse share split | 461 | GlobeNewswire (Europe) | The Board of Directors of Immunovia AB (publ) ("Immunovia" or the "Company") proposes that an Extraordinary General Meeting on 22 January 2026 resolves to carry out a reverse share split, in the ratio... ► Artikel lesen | |
| IMMUNOVIA Aktie jetzt für 0€ handeln | |||||
| 26.11.25 | Immunovia AB: Immunovia receives final Medicare payment rate for PancreaSure test | 296 | GlobeNewswire (Europe) | LUND, Sweden - Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced that the Centers for Medicare & Medicaid Services (CMS) has finalized a national payment... ► Artikel lesen | |
| 26.11.25 | Immunovia AB: Immunovia Publishes Interim Report for July-September 2025 | 340 | GlobeNewswire (Europe) | Highlights July-September 2025Net sales and operating loss for Q3 2025 in line with expectations: Net sales of 101 KSEK for the period (235) largely reflected royalty revenue. Operating loss was 25.5... ► Artikel lesen | |
| 03.10.25 | Immunovia AB: Immunovia publishes information document regarding rights issue | 548 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 01.10.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 01.10.2025 | 739 | Xetra Newsboard | Das Instrument RIHN CH0003671440 RIETER HLDG NA SF 5 EQUITY wird cum Kapitalmassnahme gehandelt am 01.10.2025 und ex Kapitalmassnahme am 02.10.2025 The instrument RIHN CH0003671440 RIETER HLDG NA SF... ► Artikel lesen | |
| 29.09.25 | Immunovia AB: Bulletin from the extraordinary general meeting in Immunovia AB (publ) | 534 | GlobeNewswire (Europe) | Today, on 29 September 2025, an extraordinary general meeting was held in Immunovia AB (publ). A summary of the adopted resolutions follows below.
Resolution on amendment of the Articles of AssociationThe... ► Artikel lesen | |
| 22.09.25 | Onconetix, Inc.: Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM | 649 | GlobeNewswire (Europe) | CINCINNATI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) ("Onconetix" or the "Company") a commercial stage biotechnology company focused on the research, development and commercialization... ► Artikel lesen | |
| 22.09.25 | Immunovia AB: Immunovia Secures Control of PancreaSure Supply Chain and Achieves Cost Reduction through Licensing Agreement | 365 | GlobeNewswire (Europe) | LUND, Sweden - Immunovia AB (publ.), the pancreatic cancer diagnostics company, has announced the successful conclusion of an agreement to acquire assets and license intellectual property that will... ► Artikel lesen | |
| 15.09.25 | Immunovia AB: Inova Schar Cancer Adopts Immunovia's PancreaSure Test for its High-Risk Surveillance Program | 337 | GlobeNewswire (Europe) | LUND, Sweden - Immunovia (publ.), the pancreatic cancer diagnostics company, today announced that its PancreaSure test will be offered to patients in Inova Schar Cancer's high-risk surveillance program... ► Artikel lesen | |
| 08.09.25 | Immunovia AB: Immunovia enters into top guarantee commitments for the upcoming rights issue | 334 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 28.08.25 | Immunovia AB: Immunovia Publishes Interim Report for January-June 2024 | 277 | GlobeNewswire (Europe) | April-June 2025Net sales, which for the quarter only included royalties, amounted to 90 KSEK (85).Operating loss was -20.1 MSEK, down from -23.9 MSEK in the second quarter of 2024. Net earnings were... ► Artikel lesen | |
| 27.08.25 | Immunovia AB: Immunovia carries out a rights issue of approximately SEK 100 million and secures bridge loans | 578 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 19.08.25 | Immunovia AB: Immunovia set to launch PancreaSure in the US on September 2nd, shares commercial strategy | 280 | GlobeNewswire (Europe) | LUND, Sweden - Immunovia (publ.) the pancreatic cancer diagnostics company, today announced that the PancreaSure test is set to launch in the US on September 2nd. The company's initial focus will be... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HIMS & HERS HEALTH | 29,160 | -0,68 % | Hims & Hers Health, Inc. (HIMS) Sees a More Significant Dip Than Broader Market: Some Facts to Know | ||
| BECTON DICKINSON | 126,95 | +3,09 % | BD's CentroVena One wins Vizient innovative technology contract | ||
| RYMAN HEALTHCARE | 1,067 | 0,00 % | RYMAN HEALTHCARE LIMITED: ASX Listing Rule 1.15.3 | ||
| NIAGEN BIOSCIENCE | 3,020 | +1,34 % | Niagen Bioscience Inc. (NAGE) Renames Research Program Amid Focus in Advancing NAD+ Applications | ||
| SIENNA SENIOR LIVING | 13,300 | +0,76 % | Sienna Senior Living Inc. Announces Voting Results From Annual Meeting | MARKHAM, Ontario, June 04, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. ("Sienna" or the "Company") (TSX: SIA) is pleased to announce that it has received shareholder approval in respect of... ► Artikel lesen | |
| MICROPORT SCIENTIFIC | 0,675 | -6,25 % | MICROPORT (00853): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON TUESDAY, 30 JUNE 2026 | ||
| EXTENDICARE | 21,200 | 0,00 % | Extendicare Inc.: Extendicare Announces June 2026 Dividend of C$0.0441 per Share | Markham, Ontario--(Newsfile Corp. - June 15, 2026) - Extendicare Inc. (TSX: EXE) ("Extendicare" or the "Company") announced that it has declared a cash dividend of C$0.0441 per common share of the... ► Artikel lesen | |
| VERADIGM | 7,350 | -100,00 % | Veradigm Inc. - 10-K, Annual Report | ||
| NATIONAL HEALTHCARE CORPORATION | 173,00 | -0,57 % | National Health Investors: NHI Announces Sale of NHC Portfolio for $560 Million | Transaction Strengthens Balance Sheet and Accelerates Capital Recycling into Private Pay Senior Housing MURFREESBORO, TN / ACCESS Newswire / April 21, 2026 / National Health Investors, Inc. (NYSE:NHI)... ► Artikel lesen | |
| HANGZHOU TIGERMED CONSULTING | 3,420 | -0,58 % | Dividendenbekanntmachungen (18.06.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 3I GROUP PLC GB00B1YW4409 0,48 GBP 0,5547 EUR ACADEMY SPORTS AND OUTDOORS INC US00402L1070 0,15 USD 0,1303 EUR AEP PLANTATIONS... ► Artikel lesen | |
| UNIPHAR | 4,520 | -0,88 % | Dividendenbekanntmachungen (23.04.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AENA SME SA ES0105046017 - 1,09 EUR AKER ASA NO0010234552 29 NOK 2,6622 EUR ALFA LAVAL AB SE0000695876 9 SEK 0,8348 EUR ARJO... ► Artikel lesen | |
| AESTHETIC MEDICAL INTERNATIONAL | 0,009 | 0,00 % | XFRA 3FMA,833: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILAEST.MED.INT.HLD.SP.ADR/3... ► Artikel lesen | |
| FRESENIUS | 39,900 | +0,91 % | DAX-Check LIVE: Auto1, BMW, Fresenius, Munich Re, Vonovia im Fokus | Der deutsche Aktienmarkt hat den Dienstag nur mit einem Mini-Plus beendet. Der DAX, der am Morgen noch über 25.100 Punkten notiert hatte, schloss am Ende lediglich 0,07 Prozent fester bei 24.910 Zählern.... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 41,550 | +0,73 % | 3 Charts in 3x33 Sekunden - Heute mit Intel, Dow Jones und FMC | 3 Charts in 3x33 Sekunden - Heute mit Intel, Dow Jones und FM ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 34,520 | +0,06 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen |
Das Unternehmen IMMUNOVIA AB kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 0,000 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMMUNOVIA AB finden Sie auf Wallstreet Online.